期刊文献+

帕金森病的神经保护治疗研究进展 被引量:6

下载PDF
导出
摘要 帕金森病(PD)多发于中老年人,病因迄今未明,目前认为是多种基因突变相互作用和(或)基因突变加上环境毒素共同作用的结果。氧化应激、线粒体功能障碍、兴奋毒性、神经营养因子缺乏、免疫调节异常及细胞凋亡都是引起PD的可能原因。目前治疗PD最有效的药物仍然是左旋多巴,但也只能减轻症状、改善患者的生存质量和延长寿命,且大多数患者长期应用后会出现运动障碍、症状波动和精神障碍等严重并发症。因此.探索能阻止PD进展的药物是必要的。本文将探讨保护和(或)修复变性神经细胞以阻止疾病进展并有望治愈PD的几种方法。
出处 《实用医学杂志》 CAS 2008年第3期334-336,共3页 The Journal of Practical Medicine
  • 相关文献

参考文献20

  • 1彭国光,董为伟.帕金森病神经保护性治疗研究进展[J].中华老年医学杂志,2003,22(8):505-507. 被引量:8
  • 2Virmani A,Gaetani F,Binienda Z. Effects of metabolic modifiers such as carnitines, coenzyme QIO, and PUFAs against different forms of neurotoxic insults:Metabolic inhibitors,MPTP,and methamphetamine [J]. Ann N Y Acad Sci,2005,1053 : 183- 191.
  • 3The NINDS NET-PD Investigators. A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease [J]. Neurology, 2007,68 ( 1 ) : 20-28.
  • 4Storch A, Jost W H, Vieregge P, et al. Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q10 in Parkinson disease [ J ]. Arch Neurol, 2007,64 (7) : 938-944.
  • 5Han J M, Lee Y J, Lee S Y, et al. Protective effect of sulforaphane against dopaminergic cell death [J]. J Pharmacol Exp Ther,2007, 321 ( 1 ) : 249-256,,.
  • 6Herzog J, Volkmann J. Two-year follow-up of subthalamic deep brain stimulation in Parkinson's disease [J ]. Mov Disord, 2003,18 (11): 1332-1337.
  • 7During M, Kaplitt M. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation [J]. Hum Gene Ther,2001,12(12) : 1589-1591.
  • 8Zurn A, Widmer H. Sustained delivery of GDNF: towards a treatment for Parkinson's disease [J]. Brain Res Brain Res Rev, 2001,36(2-3) : 222-229.
  • 9Thornel R G, Frey W H, 2nd. Delivery of neurotrophic factors to the central nervous system pharmacokinetic considerations [J]. Clin Pharmacokinet, 2001,40(12) : 907-946.
  • 10Sullivan A M, O' Keeffe G W. The role of growth/differentiation factor 5 (GDF5) in the induction and survival of midbrain dopaminergic neurones: relevance to Parkinson's disease treatment [J]. J Anat,2005,207(3) :219-226.

二级参考文献16

  • 1彭国光.帕金森氏病的神经保护性治疗[J].国外医学(神经病学.神经外科学分册),1994,21(5):248-252. 被引量:3
  • 2Delanty N, Dichter MA. Antioxidant therapy in neurologic disease. Arch Neurol, 2000,57 : 1265-1270.
  • 3Huhhle JP. Novel drugs for Parkinson's disease. Med Clin North Am, 1999,83:525-536.
  • 4Rodnitzky RL.Can calcium antagonists provide a neuroprotective effect in Parkinson's disease? Drugs, 1999,57845-849.
  • 5Kernie SG, Parada LF. The molecular basis for understanding neurotrophins and their relevance to neurologic disease. Arch Neurol, 2000,57 : 654-657.
  • 6Lang AE. Surgery for Parkinson disease: A critical evaluation of the state of the art. Arch Neurol, 2000,57:1118-1125.
  • 7Olanow CW, Tatton WG. Etiology and pathogenesis of Parkinson's disease. Annu Rev Neurosci, 1999,22,123-144
  • 8Stocchi F, Olanow CW. Neuroprotection in Parkinson's disease: Clinical trials, Ann Neurol, 2003, 53(suppl 3): S87-S99.
  • 9Ravina BM, Fagan SC, Hart RG, et al. Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment. Neurology, 2003, 60: 1234-1240.
  • 10Jankovic J. New and emerging therapies for Parkinson disease.Arch Neurol, 1999,56 : 785-790.

共引文献7

同被引文献57

引证文献6

二级引证文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部